Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has, based on the authorisation granted by the annual general meeting on 6 May 2020, resolved on a directed new share issue to selected Swedish and international institutional investors. In total, 4,697,781 new shares were issued at a subscription price of SEK 21 per share. Through the new share issue, the Company will raise approximately SEK 98.7 million before issue costs.

Press inquiries should be adressed to: